SQI Diagnostics Inc. Receives ISO 13485 Certification



    - Completes significant step towards commercialization -

    TORONTO, June 9 /CNW/ - SQI Diagnostics Inc. (TSX-Venture: SQD), a
medical systems automation company focused on evolving laboratory-based
biomarker testing, today announced that it has been awarded its ISO 13485:2003
certification for its quality management system for the Design and
Development, Production, Distribution, Installation and Servicing of its In
Vitro Diagnostics systems (Microarray Platforms and Consumable Kits). This
significant milestone further reinforces SQI Diagnostics' efforts to develop
and manufacture high-quality medical systems and tests for the healthcare
market.
    "The certification and implementation of a Quality Management System in
accordance with ISO 13485 demonstrates that we are well positioned to
manufacture and distribute our SQiDworks(TM) platform and QuantiSpot(TM)
panels at the standards required by our international customers," said Claude
Ricks, CEO of SQI Diagnostics. "This accomplishment brings us a step closer to
commercialization of our first products. We expect to complete the validation
studies of our automated microarray platform and multiplexed rheumatoid
arthritis test panel in the coming months."

    ISO Certification

    ISO 13485:2003 specifies requirements for a quality management system
where an organization needs to demonstrate its ability to develop, manufacture
and service medical devices that consistently meet customer requirements and
regulatory requirements applicable to medical devices and related services.

    About SQI Diagnostics

    SQI Diagnostics is a medical systems automation company focused on
evolving laboratory-based biomarker testing. Using automation and proprietary
miniaturization technologies, SQI Diagnostics significantly improves the
economies of scale for laboratories performing multi-analyte biomarker
testing, allowing them to deliver patient results faster, using less labor,
and fewer resources. SQI Diagnostics' initial products target the autoimmune
disease market, with initial products for rheumatoid arthritis and
antiphospholipid syndrome scheduled for launch in 2008. SQI Diagnostics is
based in Toronto, Canada. For further information please visit
www.sqidiagnostics.com.

    Certain information in this press release is based on beliefs and
assumptions of the Company's senior management and information currently
available to it that may constitute forward-looking information within the
meaning of securities laws. Such statements reflect the current views of the
Company with respect to future events and are subject to certain risks and
uncertainties. Actual results, events, and performance may differ materially.
Readers are cautioned not to place undue reliance on these forward-looking
statements.
    This release was prepared by management of the Company who takes full
responsibility for its contents. The TSX Venture Exchange has not reviewed and
does not accept responsibility for the adequacy or accuracy of this news
release.

    %SEDAR: 00021000E




For further information:

For further information: Chief Financial Officer, Andrew Morris, (416)
674-9500 ext. 229, amorris@sqidiagnostics.com; Investor Relations, James
Smith, (416) 815-0700, ext. 229, jsmith@equicomgroup.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890